BiotechTube

NNC0385-0434

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk

Conditions

Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers

Trial Timeline

Dec 9, 2021 → May 31, 2022

NCT ID
NCT05091073

About NNC0385-0434

NNC0385-0434 is a phase 1 stage product being developed by Novo Nordisk for Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk. The current trial status is completed. This product is registered under clinical trial identifier NCT05091073. Target conditions include Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk, Elevated Cholesterol, Healthy Volunteers.

What happened to similar drugs?

1 of 2 similar drugs in Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk were approved

Approved (1) Terminated (0) Active (1)
✅Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
🔄TQJ230 + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05091073Phase 1Completed

Competing Products

2 competing products in Established Atherosclerotic Cardiovascular Disease (ASCVD) or ASCVD Risk

See all competitors
ProductCompanyStageHype Score
Niacin/simvastatin compared to simvastatin alone at 2 dosesMerckApproved
43
TQJ230 + PlaceboNovartisPhase 3
44